Literature DB >> 12901958

Breast cancer trial with erythropoietin terminated unexpectedly.

Brian Leyland-Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12901958     DOI： 10.1016/s1470-2045(03)01163-x

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  94 in total

1.  Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008.

Authors:  Elizabeth Tarlov; Kevin T Stroupe; Todd A Lee; Thomas W Weichle; Qiuying L Zhang; Laura C Michaelis; Howard Ozer; Margaret M Browning; Denise M Hynes
Journal:  Support Care Cancer       Date:  2011-09-20       Impact factor: 3.603

2.  Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.

Authors:  Ke Liang; Francisco J Esteva; Constance Albarracin; Katherine Stemke-Hale; Yang Lu; Giampaolo Bianchini; Ching-Yi Yang; Yong Li; Xinqun Li; Chun-Te Chen; Gordon B Mills; Gabriel N Hortobagyi; John Mendelsohn; Mien-Chie Hung; Zhen Fan
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

3.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

4.  Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization.

Authors:  Jody Ciolino; Wenle Zhao; Renee' Martin; Yuko Palesch
Journal:  Contemp Clin Trials       Date:  2010-11-13       Impact factor: 2.226

5.  Similar Outcomes for Two Anemia Treatment Strategies among Elderly Hemodialysis Patients with Diabetes.

Authors:  M Thamer; Y Zhang; J Kaufman; D Cotter; M A Hernán
Journal:  J Endocrinol Diabetes       Date:  2014

6.  Functional erythropoietin autocrine loop in melanoma.

Authors:  Suresh M Kumar; Geza Acs; Dong Fang; Meenhard Herlyn; David E Elder; Xiaowei Xu
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 8.  Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations.

Authors:  Jane Ahlqvist-Rastad; Maria Albertsson; Jonas Bergh; Gunnar Birgegård; Peter Johansson; Bertil Jonsson; Elisabeth Kjellen; Sven Påhlman; Björn Zackrisson; Anders Osterborg
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Authors:  Arti Hurria; Kelly Brogan; Katherine S Panageas; Ann Jakubowski; Marjorie Zauderer; Carol Pearce; Larry Norton; Jane Howard; Clifford Hudis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

10.  Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats.

Authors:  Yanhui Zhou; Bin Sun; Junhong Guo; Guohong Zhou
Journal:  Biomed Rep       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.